
A: Research grants: conducting methodology and/or biomedical research
09/01/19 – 08/31/24 (PI, Chen)
“A Multivariate Mediation and Deep Learning Framework for Genome
Connectome -Substance Use Research”
NIH- 1DP1DA048968-01
Avenir Director’s Award, NIDA
Total Costs: $ 2,280,000
10/15/19 – 10/14/24 (Biostatistics Core Director, 20%; PI - Schwarcz)
“Kynurenic Acid and Cognitive Abnormalities in Schizophrenia”
NIH/NIMH P50
09/01/17 – 08/31/22 (Subcontract PI; PI - Smith)
“Exercise for Brain Health with Increased Genetic Risk for Alzheimer's
Disease”
NIH MH113617-01
01/02/17 – 12/31/19 (Subcontract PI; PI - Milton)
“Contagious Phenotypes of Acute Respiratory Infection: Identification,
characterization, and Omics Biomarkers”
DARPA-16-42-Prom-FP-015 DARPA
08/01/18 – 04/30/23 (Co-Inv; PI - Hong)
“Toward Multisystem-Brain Successful Aging in Schizophrenia
Spectrum”
NIH/NIMH 1R01MH112887-01A1
02/01/17 – 11/30/21 (Co-Inv, PI - Hong)
“The Role of Stress-Immune-Connectome Disruption in Mechanisms of
Chinese Early”
NIH/NIMH 5R01MH11218-02
05/01/18 – 04/30/23 (Co-Inv, PI - Waltz)
“Reward System Function as a Potential Mediator of the Impact of
Stress on Psychopathology”
NIH/NIMH 1R01MH115031
​
07/01/18 – 04/30/23 (Co-Inv, PI - Gold)
“Cognitive Neuroscience of Attention and Working Memory in
Schizophrenia”
NIH/NIMH 5R01MH065034
05/01/19 – 02/28/22 (Co-Inv, PI - Wang)
“Assessing ASL CBF as A Biomarker for Early Alzheimer's Disease
Detection and Disease Progression”
NCCIH 1R01AG060054-01
10/01/19 – 09/30/24 (Co-Inv, PI - Seminowicz)
“EEG and fMRI biomarkers for chronic pain”
NIH R01
B: Clinical trial based grants (Chen is leading the statistical and machine learning team):
Dr. Chen leads the statistical experiment design, power/sample size calculation, statistical analysis plan (SAP), trial randomization, analysis, and statistical report.
09/30/18 – 08/31/23 (Co-Inv, PI - Hong and Du)
“Circuitry-Guided Smoking Cessation in Schizophrenia”
NIH/NIDA UG3DA047685
09/15/18 – 08/31/20 (Co-Inv, PI - Buchanan)
“Prebiotic Treatment in People with Schizophrenia”
NCCIH 1R61 AT0999-01
07/01/15 – 06/30/19 (Co-Inv, PI - Kelly)
“Biomarker and Safety Study of Clozapine Benign Ethnic Neutropenia”
NIH/NIMH 5R01 MH102215-03
08/01/17 – 05/31/22 (Co-Inv, PI - Kelly)
“Confirmatory Double-Blind Placebo-Controlled Efficacy Trial of a
Gluten-Free Diet in a Subgroup of Persons with Schizophrenia Who
Have High Levels of lgG Anti-Gliadin Antibodies”
NIH/NIMH 1R01MH113617-01
04/01/19 – 02/31/24 (Co-Inv, Merenstein and Fraser)
“Exploratory Pilot Studies to Demonstrate Mechanisms of Preventing
Antibiotic-Associated Diarrhea and the Role for Probiotics”
NIH R61/R33 AT009622-01
09/01/19 – 08/31/24 (Co-Inv, PI - Seminowicz)
“Validation of a novel cortical biomarker signature for pain”
NIH 1R61NS113269-01
​
C: Training grants (Chen serves as a mentor)
07/01/16 – 06/30/21 (Mentor, Committee member, 0%; PI - Rowland/Carpenter)
“Multidisciplinary schizophrenia research training”
NIH/NIMH T32MH067533